Our initial experience with SMANCS in TAE for liver cancer
Fujita, M.; Inoue, E.; Kuroda, C.; Kasugai, H.; Sasaki, Y.; Nakano, H.; Imaoka, S.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(Suppl 1): 105-108
1998
ISSN/ISBN: 0385-0684 PMID: 9512697 Document Number: 485779
To evaluate the efficacy and adverse reaction of SMANCS, we reviewed 10 cases treated by TAE with SMANCS among 896 cases treated by TAE for liver cancer during the past three years at our institute. Our criteria for using SMANCS were as follows: a) reduced effectiveness of past TAE with Lipiodol, hydrophilic drugs and gelatin sponge; b) sufficient caliber and blood flow in the hepatic artery; and c) good hepatic function. The 1- and 2-year survival rates after treatment with SMANCS were 50% and 25%, respectively. The 3- and 5-year survival rates after initial treatment (first TAE, etc.) were 40% and 20%, respectively. There were no significant complications in clinical course, however, subsequent hepatic arteriogram often showed arterial change that may interfere with further regional therapy for the liver.